Telomerase and the aging cell: Implications for human health

JAMA

Volumn 279, Issue 21, 1998, Pages 1732-1735

  Fossel, Michael ^a,b,c  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b GRAND VALLEY STATE UNIVERSITY   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TELOMERASE;

ARTICLE; ATHEROSCLEROSIS; CELL AGING; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; HUMAN; MALIGNANT TRANSFORMATION; NONHUMAN; PRIORITY JOURNAL; SENESCENCE; SIGNAL TRANSDUCTION; SKIN;

EID: 0032478989     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.279.21.1732     Document Type: Article

References (82)

1. Bodnar AG, Ouellette M, Frolkis M, et al. Extension of life-span by introduction of telomerase into normal human cells. Science. 1998;279:349-352.
2. Vaziri H, Benchimol S. Reconstitution of telomerase activity in normal cells leads to elongation of telomeres and extended replicative life span. Curr Biol 1998;8:279-282.
3. Hayflick L, Moorehead PS. The limited in vitro lifetime of human diploid cell strains. Exp Aging Res. 1961;25:585-621.
4. Hayflick L. The cell biology of human aging. Sci Am. 1980;242:58-66.
5. Wright WE, Pereira-Smith OM, Shay JW. Reversible cellular senescence: implications for immortalization of normal human diploid fibroblasts. Mol Cell Biol. 1989;8:3088-3092.
6. Goldstein E. Replicative senescence: the human fibroblast comes of age. Science. 1990;249:1129-1133.
7. Campisi J. Replicative senescence: an old live's tale. Cell. 1996;84:497-500.
8. Campisi J. The biology of replicative senescence. Eur J Cancer. 1997;33:703-709.
9. Faraghar RGA, Shelf S. Gerontology and drug development: the challenge of the senescent cell. Drug Discovery Today. 1997;2:64.
10. Olovnikov AM. Principle of marginotomy in template synthesis of polynucleotides [in Russian]. Doklayd Akademii Nauk (SSR). 1971;201:1496-1499.
11. Watson JD. Origin of concatameric T7 DNA. Nat New Biol. 1972;239:197-201.
12. Harley CB, Futcher AB, Greider CW. Telomeres shorten during aging of human fibroblasts. Nature. 1990;345:458-460.
13. Hastie ND, Dempster M, Dunlop MG, Thompson AM, Green DK, Allshire RC. Telomere reduction in human colorectal carcinoma and with ageing. Nature. 1990;346:866-868.
14. Harley CB. Telomere loss: mitotic clock or genetic time bomb? Mutat Res. 1991;256:271-282.
15. Allsopp RC, Vaziri H, Patterson C, et al. Telomere length predicts replicative capacity of human fibroblasts. Proc Natl Acad Sci U S A. 1992;89: 10114-10118.
16. Allsopp RC, Harley CB. Evidence for a critical telomere length in senescent human fibroblasts. Exp Cell Res. 1995;219:130-136.
17. Blasco MA, Lee HW, Hande MP, et al. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell. 1997;91:25-34.
18. Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res. 1965;37:614-636.
19. Holt SE, Wright WE, Shay JW. Regulation of telomerase activity in immortal cell lines. Mol Cell Biol. 1996;16:2932-2939.
20. Counter CM, Hirte HW, Bacchetti S, Harley CB. Telomerase activity in human ovarian carcinoma. Proc Natl Acad Sci U S A. 1994;91:2900-2904.
21. Harley CB, Kim NW, Prowse KR, et al. Telomerase, cell immortality, and cancer. Cold Spring Harb Symp Quant Biol. 1994;59:307-315.
22. Shay JW, Gazdar AF. Telomerase in the early detection of cancer. J Clin Pathol. 1997;50:106-109.
23. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266:2011-2015.
24. Chiu C-P, Dragowska W, Kim NW, et al. Differential expression of telomerase activity in hematopoietic progenitors from adult human bone marrow. Stem Cells. 1996;14:239-248.
25. Bodnar A, Kim NW, Effros RB, Chiu C-P. Mechanism of telomerase induction during T cell activation. Exp Cell Res. 1996;228:58-64.
26. Wright WE, Piatyszek MA, Rainey WE, Byrd W, Shay JJ. Telomerase activity in human germline and embryonic tissues and cells. Dev Genet. 1996; 18:173-179.
27. Engelhardt M, Kumar R, Albanell J, Pettengell R, Han W, Moore MA. Telomerase regulation, cell cycle, and telomere stability in primitive hematopoetic cells. Blood. 1997;90:182-193.
28. Ramirez RD, Wright WE, Shay JW, Taylor RS. Telomerase activity concentrates in the mitotically active segments of human hair follicles. J Invest Dermatol. 1997;108:113-117.
29. Shay JW, Bacchetti S. A survey of telomerase in human cancer. Eur J Cancer. 1997;33:787-791.
30. Counter CM, Gupta J, Harley CB, Leber B, Bacchetti S. Telomerase activity in normal leukocytes and in hematologic malignancies. Blood. 1995;85: 2315-2320.
31. Hiyama K, Hirai Y, Kyoizumi S, et al. Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. J Immunol. 1995;155: 3711-3715.
32. Feng J, Funk WD, Wang SS, et al. The RNA component of human telomerase. Science. 1995;269: 1236-1241.
33. Nakamura TM, Morin GB, Chapman KB, et al. Telomerase catalytic subunit homologs from fission yeast and human. Science. 1997;277:955-959.
34. Thomson JA, Kalishman J, Golos TG, et al. Isolation of a primate embryonic stem cell line. Proc Natl Acad Sci U S A. 1995;92:7844-7848.
35. Decary S, Mouly V, Butler-Browne GS. Telomere length as a tool to monitor satellite cell amplification for cell-mediated gene therapy. Hum Gene Ther. 1996;7:1347-1350.
36. Counter CC, Meyerson M, Eaton EN, Ellisen LW, Caddle SD, Haber SD, Weinberg RA. Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. Oncogene. 1998;16:1217-1222.
37. Wright WE, Brasiskyte D, Piatyszek MA, Shay JW. Experimental elongation of telomeres extends the lifespan of immortal x normal cell hybrids. EMBO J. 1996;15:1734-1741.
38. Dimri GP, Lee X, Basile G, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A. 1995;92:9363-9367.
39. Fossel M. Reversing Human Aging. New York, NY: William Morrow & Co; 1996.
40. Banks D, Fossel M. Telomeres, cancer, and aging: altering the human life span. JAMA. 1997;278: 1345-1348.
41. Hammond CB. Menopause and hormone replacement therapy: an overview. Obstet Gynecol. 1996;87(2, suppl):2S-15S.
42. Wenger NK. Coronary heart disease: an older woman's major health risk. BMJ. 1997;315:1085-1090.
43. Papadakis MA, Grady D, Black D, et al. Growth hormone replacement in healthy older men improves body composition but not functional ability. Ann Intern Med. 1996;124:708-716.
44. Labrie F, Belanger A, Cusan L, Gomez JL, Candas B. Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J Clin Endocrinol Metab. 1997;82:2396-2402.
45. Berr C, Lafont S, Debuire B, Dartigues JF, Baulieu EE. Relationships of dehydroepiandrosterone sulfate in the elderly with functional, psychological, and mental status, and short-term mortality: a French community-based study. Proc Natl Acad Sci U S A. 1996;93:13410-13415.
46. Lane MA, Ingram DK, Ball SS, Roth GS. Dehydroepiandrosterone sulfate: a biomarker of primate aging slowed by calorie restriction. J Clin Endocrinol Metab. 1997;82:2093-2096.
47. Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA. 1998; 279:688-695.
48. Helzlsouer KJ, Couzi R. Hormones and breast cancer. Cancer. 1995;76:2059-2063.
49. Speroff L. Postmenopausal hormone therapy and breast cancer. Obstet Gynecol. 1996;87(2, suppl): 44S-54S.
50. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol. 1995;85:304-313.
51. Hemminki E, McPherson K. Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials. BMJ. 1997;315:149-153.
52. Wolfe J. Growth hormone: a physiological fountain of youth? J Anti-Aging Med. 1998;1:9-25.
53. Dehydroepiandrosterone (DHEA). Med Lett Drugs Ther. 1996;38:91-92.
54. Wolf OT, Neumann O, Hellhammer DH, et al. Effects of a two-week physiological dehydroepiandrosterone substitution on cognitive performance and well-being in healthy elderly women and men. J Clin Endocrinol Metab. 1997;82:2363-2367.
55. Lamberts SWJ, van den Beld AW, van der Lely AJ. The endocrinology of aging. Science. 1997;278: 410-424.
56. Pierpaoli W, Regelson W, Colman C. The Melatonin Miracle. New York, NY: Simon & Schuster; 1995.
57. Martin GM, Sprague CA, Epstein CJ. Replicative life-span of cultured human cells: effects of donor's age, tissue, and genotype. Lab Invest. 1970;23: 86-92.
58. Morin GB. Telomere control of replicative lifespan. Exp Gerontol. 1997;32:375-382.
59. Atadja P, Wong H, Garkavtsev I, Veillette C, Riabowol K. Increased activity of p53 in senescing fibroblasts. Proc Natl Acad Sci U S A. 1995;92:8348-8352.
60. Linskens MHK, Feng J, Andrews WH, et al. Cataloging altered gene expression in young and senescent cells using enhanced differential display. Nucleic Acids Res. 1995;23:3244-3251.
61. Harley CB, Sherwood SW. Telomerase, check-points and cancer. Cancer Surv. 1997;29:263-284.
62. Morin GB. Telomere control of replicative lifespan. Exp Gerontol. 1997;32:375-382.
63. Chen Q, Fischer A, Reagan JD, Yan LJ, Ames BN. Oxidative DNA damage and senescence of human diploid fibroblast cells. Proc Natl Acad Sci USA. 1995;92:4337-4341.
64. Harper JW. Cyclin dependent kinase inhibitors. Cancer Surv. 1997;29:91-107.
65. Villeponteau B. The heterochromatin loss model of aging. Exp Gerontol. 1997;32:383-394.
66. Wright WE, Shay JW. Telomere positional effects and the regulation of cellular senescence. Trends Genet. 1992;8:193-197.
67. Brash DE, Gilchrest BA. Photobiology: wrinkles waiting for GoDoT. Nature. 1996;379:301-302.
68. Shay J. Accelerated telomere shortening in bone-marrow recipients. Lancet. 1998;351:153-154.
69. Moore MA. Stem cell proliferation: ex vivo and in vivo observations. Stem Cells. 1997;15:239-248.
70. Wynn RF, Cross MA, Hatton C, et al. Accelerated telomere shortening in young recipients of allogenic bone-marrow transplants. Lancet. 1998;351: 178-181.
71. Chang E, Harley CB. Telomere length and replicative aging in human vascular tissues. Proc Natl Acad Sci U S A 1995;92:11190-11194.
72. Cooper LT, Cooke JP, Dzau VJ. The vasculopathy of aging. J Gerontol. 1994;49:191-196.
73. Campisi J. Aging and cancer: the double-edged sword of replicative senescence. J Am Geriatr Soc. 1997;45:482-488.
74. Harley C. Telomerase and cell immortality in humans. In: Program and abstracts of the 89th Annual Meeting of the American Association for Cancer Research; March 28-April 1, 1998; New Orleans, La.
75. Lundblad V, Wright WE. Telomeres and telomerase: a simple picture becomes complex. Cell. 1996; 87:369-375.
76. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe S. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INC4a. Cell. 1997;88;593-602.
77. von Zgliniki T, Saretzki G, Docke W, Lotze C. Mild hyperoxia shortens telomeres and inhibits proliferation of fibroblasts: a model for senescence? Exp Cell Res. 1995;220:186-193.
78. Shibanuma M, Mochizuki E, Maniwa R, et al. Induction of senescence-like phenotypes by forced expression of hic-5, which encodes a novel LIM motif protein, in immortalized human fibroblasts. Mol Cell Biol. 1997;17:1224-1235.
79. Bryan TM, Engelzou A, Gupta J, Bacchetti S, Reddel RR. Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J. 1995;14:4240-4248.
80. Kipling D. Telomere structure and telomerase expression during mouse development and tumorigenesis. Eur J Cancer. 1997;33:792-800.
81. Wynford-Thomas D, Kipling D. Telomerase, cancer and the knockout mouse. Nature. 1997;389: 551-552.
82. Lee H-W, Blasco MA, Gottlieb GJ, Horner JW II, Greider CW, DePinho RA. Essential role of mouse telomerase in highly proliferative organs. Nature. 1998;392:569-574.